Doseology Sciences (VU70) Price & Analysis

0 Followers

VU70 Stock Chart & Stats

€0.28

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.28

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.05 - €1.18

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€914.00K

Enterprise Value€870.27K

Total Cash (Recent Filing)€1.43M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta-1.74

Next Earnings

Oct 29, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding8,011,621

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.49

Price to Book (P/B)3.46

Price to Sales (P/S)113.73

P/FCF Ratio-14.14

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA near-zero debt profile gives the company durable financial flexibility: lower fixed obligations reduce bankruptcy risk and interest pressure, improving ability to pursue R&D, partnerships, or inventory build without immediate revenue support; this strengthens multi-month runway versus leveraged peers.

Improving Cash Burn TrendMaterial improvement in cash burn signals better operational discipline or cost control, which can extend runway and reduce fundraising frequency. If sustained, this trend makes the business less reliant on dilutive capital and supports longer-term investment in commercialization.

Strong Reported Revenue GrowthA high reported revenue growth rate indicates meaningful top-line momentum from a small base, suggesting early product traction or expanding distribution. If the company can translate growth into scale, this creates a pathway to improve gross margins and absorb fixed operating costs over time.

Bears Say

Small, Volatile Revenue BaseVery small and erratic revenue undermines predictability of cash flow and makes scaling economics uncertain. Volatility complicates forecasting, supplier contracts, and marketing ROI, and raises the bar for achieving sustainable margins and profitable unit economics over the coming months.

Consistent Negative Cash FlowPersistent negative operating and free cash flow forces reliance on external financing to fund operations and growth. Repeated capital raises can dilute shareholders and may be unsustainable if market conditions tighten, constraining long-term strategic initiatives and product development.

Ongoing Operating Losses And ROE ErosionSizable operating losses and negative ROE erode shareholder equity and limit retained earnings available for reinvestment. Continued losses impede the company's ability to self-fund scale, may pressure management to cut R&D or marketing, and raise risk that operations fail to reach profitable scale.

Doseology Sciences News

Doseology launches $2 million private placement to fund oral stimulant pouch rollout

Doseology Sciences ( ($TSE:MOOD) ) has issued an announcement. Doseology Sciences Inc. has arranged a non-brokered private placement...

3M ago

Doseology Uplists to OTCQB to Advance Growth in Oral Stimulant Pouch Market

An announcement from Doseology Sciences ( ($TSE:MOOD) ) is now available. Doseology Sciences Inc. has uplisted its common...

4M ago

Doseology debuts nicotine-free energy pouches in U.S. direct-to-consumer pilot

Doseology Sciences ( ($TSE:MOOD) ) has shared an announcement. Doseology Sciences has launched its Feed That Brain Energy...

4M ago

Doseology Taps Veteran Pharmacy Executive Larry Latowsky as Executive Chairman to Steer Commercial Expansion

Doseology Sciences ( ($TSE:MOOD) ) just unveiled an update. Doseology Sciences has appointed veteran retail and healthcare executive...

4M ago

Doseology Launches Pilot for Caffeine Energy Pouches Under Feed That Brain Brand

Doseology Sciences ( ($TSE:MOOD) ) just unveiled an update. Doseology Sciences has begun a pilot production run of...

5M ago

Doseology Boosts Transparency With New Annual Information Form Filing

Doseology Sciences ( ($TSE:MOOD) ) has issued an update. Doseology Sciences Inc. has filed its Annual Information Form...

6M ago

Doseology Taps McKinney Advisors to Fast-Track Regulatory Path for Oral Pouch Line

Doseology Sciences ( ($TSE:MOOD) ) just unveiled an announcement. Doseology Sciences has entered a strategic partnership with McKinney...

6M ago

Doseology Launches Investor Communications Initiative to Boost Market Engagement

The latest update is out from Doseology Sciences ( ($TSE:MOOD) ). Doseology Sciences Inc. has launched an Investor...

7M ago

Doseology Secures Strategic Manufacturing Agreement for Market Readiness

Doseology Sciences ( ($TSE:MOOD) ) has issued an announcement. Doseology Sciences Inc. has announced a significant milestone with...

8M ago

Doseology Sciences Expands Portfolio with Strategic Acquisition

An update from Doseology Sciences ( ($TSE:MOOD) ) is now available. Doseology Sciences Inc. has completed the acquisition...

10M ago

VU70 FAQ

What was Doseology Sciences, Inc.’s price range in the past 12 months?

Doseology Sciences, Inc. lowest stock price was €0.05 and its highest was €1.18 in the past 12 months.

What is Doseology Sciences, Inc.’s market cap?

Doseology Sciences, Inc.’s market cap is €914.00K.

When is Doseology Sciences, Inc.’s upcoming earnings report date?

Doseology Sciences, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 118 days.

How were Doseology Sciences, Inc.’s earnings last quarter?

Doseology Sciences, Inc. released its earnings results on Jun 01, 2026. The company reported -€0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.021.

Is Doseology Sciences, Inc. overvalued?

According to Wall Street analysts Doseology Sciences, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Doseology Sciences, Inc. pay dividends?

Doseology Sciences, Inc. does not currently pay dividends.

What is Doseology Sciences, Inc.’s EPS estimate?

Doseology Sciences, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Doseology Sciences, Inc. have?

Doseology Sciences, Inc. has 8,011,621 shares outstanding.

What happened to Doseology Sciences, Inc.’s price movement after its last earnings report?

Doseology Sciences, Inc. reported an EPS of -€0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Doseology Sciences, Inc.?

Currently, no hedge funds are holding shares in DE:VU70

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Doseology Sciences, Inc.

Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, including tinctures. It sells its products online through doseology.com and e-commerce platforms, as well as through various retail chains and distributors. The company was formerly known as Pcybin Therapeutic Inc. and changed its name to Doseology Sciences Inc. in January 2020. Doseology Sciences Inc. was incorporated in 2019 and is based in Kelowna, Canada.